Small molecule · Inhibitor of checkpoint kinase 1 (CHEK1) · developed by Sierra Oncology LLC - a GSK company
SRA737 is an orally bioavailable inhibitor of checkpoint kinase 1 (CHK1) that selectively binds CHK1, blocking its activity in DNA damage repair and cell cycle checkpoint control. It is studied in advanced solid tumors and non-Hodgkin's lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02797964 | Phase 1/2 | Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) | Completed | GSK |
| NCT02797977 | Phase 1/2 | Advanced Solid Tumors | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsAdvanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →